IL5 and chronic rhinosinusitis with nasal polyps: Our group, therefore, have performed several proof-of-concept studies in Ghent since 2005, starting with several investigator-initiated studies; we demonstrated the effect of a monoclonal antibody to IL-5, reslizumab, on the polyp score and symptoms, showing that in principle biologics could work in CRSwNP.12